| ctka-0008 |
Use of Chemotherapy plus a Monoclonal Antibody (Trastuzumab) against HER2-Positive Metastatic Breast Cancer
|
|
Use of Chemotherapy plus a Monoclonal Antibody (Trastuzumab) against HER2-Positive Metastatic Breast Cancer
|
|
| Year |
Uso di Chemioterapia e un Anticorpo Monoclonale (Trastuzumab) nel Cancro al Seno Metastatico HER2-Positivo
|
| Journal | 2001 |
| DOI | NEJM |
| PMID | 10.1056/nejm200103153441101 |
| URL | 11248153 |
| https://www.nejm.org/doi/full/10.1056/nejm200103153441101 | |
| Category | Clinical Trial |
| Precision Oncology | |
| Targeted Therapy | |
| HER2 | |
| Breast Cancer | |
| Breast | |
| Abstract | Targeting protein overexpression in solid tumors. |
| Targeting dell’iperespressione proteica nei tumori solidi. | |
| This Phase 3 trial aimed to evaluate if adding Trastuzumab (Herceptin), a monoclonal antibody targeting the HER2 protein, to standard chemotherapy would improve clinical outcomes for women with metastatic breast cancer that overexpresses HER2. This was one of the first major attempts to apply targeted therapy to a common solid tumor. | |
| Questo studio di Fase 3 mirava a valutare se l’aggiunta di Trastuzumab (Herceptin), un anticorpo monoclonale che colpisce la proteina HER2, alla chemioterapia standard potesse migliorare i risultati clinici nelle donne con carcinoma mammario metastatico che iperprime HER2. | |
| Approximately 25-30% of breast cancers overexpress HER2, which was associated with rapid tumor growth and poor prognosis. The problem was that standard chemotherapy was insufficient for this aggressive subtype. The study addressed whether a targeted antibody could sensitize these tumors to chemotherapy and extend survival. | |
| Circa il 25-30% dei tumori al seno iperprime HER2, il che era associato a una crescita tumorale rapida e una prognosi infausta. Il problema era che la chemioterapia standard era insufficiente per questo sottotipo aggressivo. Lo studio ha valutato se un anticorpo mirato potesse sensibilizzare questi tumori. | |
| Take home message | Trastuzumab significantly increased survival and response rates, transforming HER2-positive breast cancer from the worst prognosis to a highly manageable subtype. The take-home message is the necessity of matching the right drug to the right patient via molecular testing, a cornerstone of modern breast cancer education. |
| Trastuzumab ha aumentato significativamente la sopravvivenza, trasformando il cancro al seno HER2-positivo da quello con la peggiore prognosi a un sottotipo gestibile. Il messaggio è la necessità di abbinare il farmaco giusto al paziente giusto tramite test molecolari. | |
| Limitazioni | Cardiotoxicity concerns when combined with anthracyclines. |
| Preoccupazioni di cardiotossicità in combinazione con antracicline. |
